The investigators are conducting a placebo-controlled, randomized control trial with
duloxetine in healthy, fertile men not previously on any antidepressants. Participants will
be randomized to either the duloxetine or placebo groups for 6 weeks. The investigators will
assess changes in sperm DNA fragmentation at 0, 2, 6, 8, and 10 weeks. Other outcomes
measured will include semen parameters (sperm concentration, motility, morphology), hormone
levels (testosterone, estrogen, prolactin, LH, FSH), and sexual function (IIEF and MSHQ)
surveys.